Literature DB >> 6336874

Acute effects of captopril on cardiopulmonary hemodynamics and renin-angiotensin-aldosterone and bradykinin profile in hypertension.

S Mookherjee, G H Anderson, R Eich, N Hill, H Smulyan, D H Streeten, S Vardan, R Warner.   

Abstract

Hemodynamic variables were measured and plasma renin activity (PRA), angiotensin II (AII), aldosterone, and bradykinin assays performed in 21 hypertensive men on regular diet and thiazide diuretics before and 60 to 90 minutes after 25 mg oral captopril. Heart rate, right and left ventricular filling pressures, mean cardiac index (CI), and pulmonary vascular resistance (PVR) remained unchanged. The mean intra-arterial pressure (MAP) fell from 140 +/- 5 to 116 +/- 6 mm Hg (p less than 0.001) correlating with reduction of systemic vascular resistance (SVR) (r = 0.87, p less than 0.001), control PRA (r = 0.59, p less than 0.01), and All levels (r = 0.72, p less than 0.005) but not with control bradykinin or its postcaptopril rise (p less than 0.01). The fall in SVR correlated with reduction in plasma All (r = 0.80, p less than 0.001) and aldosterone concentrations (r = 0.53, p less than 0.05). Of four patients (19%) with precipitous fall in MAP after captopril, three needed volume expansion for circulatory support. We conclude: (1) All reduction by captpril and not bradykinin potentiation explains most of the agent's hemodynamic response in hypertensive circulation, (2) endogenous All may have a supportive role for SVR and possibly for CI but not for PVR, and (3) extra precaution is warranted while captopril is being started in patients taking diuretics.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6336874     DOI: 10.1016/0002-8703(83)90286-7

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

1.  Influence of a single dose of captopril on pulmonary haemodynamics and right ventricular function in mitral stenosis with pulmonary hypertension.

Authors:  K Zmudka; J P Dubiel; T Brzostek; T Horzela
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 2.  Captopril. An update of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  R N Brogden; P A Todd; E M Sorkin
Journal:  Drugs       Date:  1988-11       Impact factor: 9.546

Review 3.  Inhibitors of the angiotensin I converting enzyme as antihypertensive drugs.

Authors:  P A Van Zwieten; A De Jonge; P B Timmermans
Journal:  Pharm Weekbl Sci       Date:  1983-10-21

Review 4.  Adverse reactions with angiotensin converting enzyme (ACE) inhibitors.

Authors:  R DiBianco
Journal:  Med Toxicol       Date:  1986 Mar-Apr

5.  Effects of captopril on pulmonary haemodynamics.

Authors:  C Richard; J L Ricome; A Rimailho; M Conrad; P Auzépy
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 6.  Angiotensin converting enzyme inhibitors: comparative structure, pharmacokinetics, and pharmacodynamics.

Authors:  G S Thind
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.